



**20th International Conference on
Breast Pathology and
Cancer Diagnosis**

April 11th, 2023 | Webinar

**KEYNOTE
ABSTRACTS**

20th International Conference on Breast Pathology and Cancer Diagnosis

April 11th, 2023 | Webinar

ISSN: 2572-4118

Expansion pathology: Physical tissue expansion for advanced investigation of clinical specimens.

Abstract

Background

In diagnostic pathology, conventional optical microscopy is critical to diagnosis. Unfortunately, due to physical limitations, optical microscopy can reach only ~250 nm in resolution, making the use of higher resolution imaging strategies (such as electron microscopy) required for investigation, diagnosis and/or confirmation of certain pathologies. In a Harvard-MIT multidisciplinary collaboration, we developed a pathology-optimized form of physical tissue expansion named **Expansion Pathology (ExPath)**, which enables homogenous and isometric tissue expansion (approximately 100-fold in three-dimension) that can push the optical resolution limit of the optical microscopes to ~70-80 nm.

We used **ExPath** to demonstrate high precision discrimination between early breast neoplastic lesions that to date have challenged pathological classification and for optical investigation and diagnosis of kidney nephrotic lesions, which were previously diagnosed or confirmed with an electron microscope.


Expansion Pathology is an inexpensive, fast, reliable method which may open up the routine use of **nanoscale** imaging in pathology, enabling advanced investigation of clinical specimens and improved diagnosis of pathologies such as cancer.

Biography:

Dr. Octavian Bucur, MD, PhD, is an Associate Investigator at the Viron Molecular Medicine Institute in Boston, MA, USA and Editor in Chief of the journal *Discoveries*.

He has over a decade of training and research experience at the Harvard Medical School: Postdoctoral Fellow at BIDMC and Harvard Medical School, Instructor in Pathology (Faculty), Harvard Medical School (2017-2018); Associate Member, Wyss Institute of Biologically Inspired Engineering at Harvard (2014-2015), Associate Member of the Ludwig Cancer Center at Harvard University, Boston, MA (2016-2018), affiliated with Broad Institute of MIT and Harvard, Boston, MA (2016-2018).

Dr. Octavian Bucur has made impactful contributions in several research fields, being one of the main developers of Expansion Pathology (*Nature Biotechnology* 2017 (in the top 5% of all research outputs scored by Altmetric), *Nature Protocols* 2020; 3 patents). This method extends the current resolution limit (250 nm) of the optical microscopes to 70 nm, enabling visualization of smaller nanoscopic structures with inexpensive optical microscopy in preserved tissue specimens, after physical tissue expansion. Expansion-related technologies have tremendous implications in several biomedical fields, including diagnostic pathology, neuroscience and molecular medicine.



Octavian Bucur

Viron Molecular Medicine Institute, Boston,
USA

Received: 06-03-2023 | **Accepted:** 07-03-2023 | **Published:** 11-04-2023

20th International Conference on Breast Pathology and Cancer Diagnosis

April 11th, 2023 | Webinar

ISSN: 2572-4118



Octavian Bucur

Viron Molecular Medicine Institute, Boston,
USA

Among the honors and awards received over the years are: Recognition of Outstanding Achievement in Translational and Basic Science Research from the Harvard Medical School Pathology Department; ranked 1st out of >100 - Best Scientific Poster Award (2017, Harvard Medical School Pathology Retreat of MGH, BIDMC, BWH, DFCI, Children's Hospital Boston); The American Association for Cancer Research (AACR)-Millennium Pharmaceuticals Award (2015, Philadelphia, PA), IUBMB Travel Fellowship (2010, Melbourne, Australia), The American Association for Cancer Research (AACR)-Aflac Award (2008, San Diego, CA); Lady Tata Memorial Trust International Award for Leukemia Research (2007, London, UK); European Union - Leonardo da Vinci Research Award (2004, Magdeburg, Germany); Invited Keynote Speaker/Special Lectures (conferences in San Francisco, Chicago, London (UK), Bucharest (Romania), BIDMC, Harvard Medical School - Boston, Wayne State University - Detroit, Carol Davila University, Romania); Chair of the Scientific Selection Committee for the RAL's Grand Rounds competition, Research Assistant Learning Initiative, Boston (2017-2018); Invited Judge for many undergraduate/graduate research competitions; International grant evaluator.

Dr. Octavian Bucur is a Co-Founder, major stakeholder and was the first CEO of Viron Therapeutics, Boston, MA and QPathology, Boston, MA. He is also leading a prolific research group at the Victor Babes National Institute of Pathology in Bucharest, selecting and training some of the most promising students and young researchers from Romania (nextgenpathology.eu).

Received: 06-03-2023 | **Accepted:** 07-03-2023 | **Published:** 11-04-2023

20th International Conference on Breast Pathology and Cancer Diagnosis

April 11th, 2023 | Webinar

ISSN: 2572-4118

Screening, monitoring and diagnosis of breast cancer

Abstract:

Early detection and optimal treatment by surgical-oncology team are the two most important factors preventing deaths from breast cancer. Screening Mammogram guidelines have been established as per risk stratification of patient populations and latest scientific evidence. Additional Screening recommendations with Ultrasound and MRI can be performed, depending on breast density or risk assessment. Diagnostic work up of a patient presenting with breast related complaints are performed using Diagnostic Mammogram, Ultrasound or MRI. Image guided biopsies can also be performed if there is a concern for malignancy based on diagnostic work up. Imaging is also targeted to assess locoregional spread, multifocal or multicentric disease, lymph node involvement as well as distant spread. Staging work up can be performed with PET CT in cases with concern for metastatic spread. Once the diagnosis is established, image guided preoperative localization prior to the surgery is performed with specimen radiography. Patients receiving neoadjuvant therapy can be monitored to assess therapeutic response. MRI imaging with intravenous gadolinium aids in assessment of the tumor not only on the basis of morphology but also the kinetics of enhancement including uptake and wash out. Follow up imaging is routinely performed to assess for tumour recurrence. State of the art newer and experimental breast imaging techniques are always focus of research to provide best screening, monitoring and diagnostic work up for breast cancer patients

Biography

Dr. Kaushik is a board-certified radiologist working at Breast Care Center affiliated with Thomas Jefferson University Hospital in Philadelphia. With over 15 years of experience in the field of Medical imaging, Dr. Kaushik has expertise in mammography, breast ultrasound, and breast procedures including biopsies and MRI. Dr. Kaushik received her medical and Post Graduate degrees from University of Delhi India with honor roll. She went to pursue her Fellowship in Diagnostic Imaging from University of Arkansas for Medical Sciences. She is a member of American College of Radiology and Society of Breast Imaging. Women's health and Breast Cancer Imaging have always been causes close to her heart, in her words "it's not only a passion but a calling".



Dr. Chhavi Kaushik,

Thomas Jefferson University, PA, USA

Received: 04-01-2023 | **Accepted:** 06-01-2023 | **Published:** 11-04-2023